3P Biopharmaceuticals continues its collaboration with U.S. biotech Zhittya for the treatment of Parkinson’s disease.May 2, 2023Read more >
The Regional Minister for Economic and Business Development Mikel Irujo meets with the management of 3P Biopharmaceuticals and its majority shareholder Keensight Capital.March 23, 2023Read more >
3PBIOVIAN’s in-house Solution preparation team prepares and provides a wide variety of solutionsMarch 22, 2023Read more >
3P Biopharmaceuticals is moving forward with its expansion plan and the adaptation of its facilities.March 9, 2023Read more >
3P Biopharmaceuticals increases its microbial production capacity with the installation of a 500 L fermenter.March 1, 2023Read more >
3P Biopharmaceuticals brings together leading international experts in biomedicine to celebrate its 15th anniversary.December 1, 2022Read more >
Osivax and 3P Biopharmaceuticals team up to develop a new universal vaccine against current and future variants of SARS-COV-2November 26, 2022Read more >
BrainEver and 3P Biopharmaceuticals collaborate on development of recombinant human homeoprotein Engrailed-1November 15, 2022Read more >
Biovian Announces the Appointment of a New Board Member − Dr. Uwe GottschalkSeptember 22, 2022Read more >
3P Biopharmaceuticals celebrates its 15th anniversary with Juan Carlos Unzué.July 29, 2022Read more >
3P Biopharmaceuticals and Biosergen complete together the manufacture of biomass for the Mucormycosis “Black Fungus” clinical phase II trial.July 11, 2022Read more >
3P Biopharmaceuticals awards prize for the best Final Degree Project in Pharmacy at the University of NavarraJune 24, 2022Read more >